Skip to main
SOLV

Solventum Corporation (SOLV) Stock Forecast & Price Target

Solventum Corporation (SOLV) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 18%
Buy 45%
Hold 27%
Sell 0%
Strong Sell 9%

Bulls say

Solventum is a healthcare company that has caught the attention of analysts due to their "offensive M&A" strategy and capital allocation priorities, including a $1B share repurchase program. Despite the potential risks related to decreases in global healthcare spending and competitive pressure, the company has maintained strong performance, with first quarter results exceeding expectations and organic growth in all segments. This is reflected in their solid financials, with first quarter revenue at $2.007B (2.1% organic growth) and EPS at $1.48. Analysts have revised their estimates to account for this strong performance, with an increase in EPS to $6.59 for 2026 and $7.15 for 2027. With continued growth expected and a potential for further portfolio optimization, Solventum remains a solid investment opportunity with a "Buy" rating and a $93 price target.

Bears say

Solventum is a healthcare company that was spun out of 3M in 2024 with a global presence and a focus on medical technology segments. Despite a clear strategy to create value through divesting businesses, reducing debt, and solid execution, the company has faced challenges in certain segments resulting in underperformance. However, with a strong focus on improving operations and delivering growth, Solventum may present a long-term opportunity for investors.

Solventum Corporation (SOLV) has been analyzed by 11 analysts, with a consensus rating of Buy. 18% of analysts recommend a Strong Buy, 45% recommend Buy, 27% suggest Holding, 0% advise Selling, and 9% predict a Strong Sell.

This aggregate rating is based on analysts' research of Solventum Corporation and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Solventum Corporation (SOLV) Forecast

Analysts have given Solventum Corporation (SOLV) a Buy based on their latest research and market trends.

According to 11 analysts, Solventum Corporation (SOLV) has a Buy consensus rating as of Jul 8, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $86.27, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $86.27, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Solventum Corporation (SOLV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.